For Now, Nuvelo Will Go It Alone On Thrombolytic Alfimeprase
This article was originally published in The Pink Sheet Daily
Executive Summary
Development of the stalled anti-clotting agent resumes as partner Bayer pulls out of the collaboration.
You may also be interested in...
Nuvelo Discontinues Alfimeprase After Disappointing Efficacy Results
After discontinuing its only late-stage drug candidate, Nuvelo is back at Phase I.
Nuvelo Discontinues Alfimeprase After Disappointing Efficacy Results
After discontinuing its only late-stage drug candidate, Nuvelo is back at Phase I.
Nuvelo Begins Phase II Trial Of Thrombolytic For Ischemic Stroke
After poor Phase III results for catheter occlusion and loss of Bayer partnership, company cites optimism about efficacy in stroke.